
    
      This was a Phase 3, open-label, multicenter study to evaluate the efficacy and safety of
      GLE/PIB for an 8- or 12-week treatment duration in adults in Brazil with chronic HCV GT1 to
      GT6 infection, without cirrhosis or with compensated cirrhosis with a METAVIR System Fibrosis
      Score of F2 to F3 (without cirrhosis) or F4 (with compensated cirrhosis) or equivalent, who
      were HCV treatment-na√Øve.
    
  